作者: Elaine F. Walker , Barbara A. Cornblatt , Jean Addington , Kristin S. Cadenhead , Tyrone D. Cannon
DOI: 10.1016/J.SCHRES.2009.07.023
关键词: Clinical trial 、 Severity of illness 、 Longitudinal study 、 Psychiatry 、 Relative risk 、 Psychology 、 Prodrome 、 Antipsychotic 、 Randomized controlled trial 、 Psychosis
摘要: A substantial number of patients who meet criteria for a prodromal syndrome first psychosis are treated with antipsychotic and/or antidepressant medications. There is suggestive evidence that both classes medication may reduce symptoms. This longitudinal study examined the relation and symptom severity at baseline 6-month follow-up. Participants met Structured Interview Prodromal Syndromes (SIPS) prodrome, were evaluated eight centers as part North American Prodrome Longitudinal Study (NAPLS). Symptom ratings (positive, negative, disorganized general) data on antipsychotics, SSRIs, other medications obtained Analyses revealed all dimensions declined in over time, but there differences magnitude decline function medication. Those never antipsychotics showed less reduction positive symptoms time. SSRIs antidepressants not linked declines severity. Consistent findings from small-sample, clinical trials, present results suggest atypical be effective reducing attenuated associated prodrome to psychotic disorders. Limitations noted, including fact it randomized trial, duration dosage 2-year follow-up available most participants. The discussed light relative risks benefits preventive interventions, cognitive therapies, importance future trials.